New survey data challenges food industry assumptions about GLP-1 shoppers

New survey research on how people taking GLP-1 medications shop and eat suggests the drugs are reshaping grocery demand in narrower, more category-specific ways than food manufacturers have assumed. The findings, reported August 19, 2026, draw on work from the flavor company International Flavors & Fragrances, PwC's Strategy&, Boston Consulting Group and The Harris Poll UK ^[1].

A PwC survey of more than 2,300 UK adults found that almost 60 percent of GLP-1 users are buying less food. But roughly 30 percent are trading up, spending more on individual products even as they buy fewer of them ^[1]. BCG found a similar redistribution: active users expect to spend 15 percent more each month on fruit and vegetables and 11 percent more on high-protein foods, and they are about twice as likely to choose functional products over conventional premium ones ^[1].

That split matters because the two effects pull in different directions. Categories built on volume and frequent impulse purchases face pressure, while smaller formats with better ingredients or a more distinctive taste can hold or increase their value ^[1]. Manufacturers, the analysis notes, need to work out whether their categories are losing consumption, revenue or both ^[1].

Nothing about the shift is permanent for everyone. Roughly one-third of people who have taken a GLP-1 have stopped at any given time, and about 60 percent of former users intend to restart, according to BCG. More than one in 10 active users cycle on and off deliberately. Reaching a target weight and difficulty paying for the medication are among the main reasons people stop ^[1].

Diet changes persist unevenly after treatment ends. PwC found more than 80 percent of former UK users keep at least some of the changes they made while taking the drug. BCG's product-level analysis shows which ones: meat, fruit, vegetables and high-protein foods can stay elevated or keep growing after treatment, while protein drinks and meal replacements tend to peak during use and then fall back. Baked goods, salty snacks, confectionery and frozen meals are more likely to rebound, and BCG says cravings and old eating habits can start returning within one to three months ^[1].

The effects also reach beyond the person taking the drug. BCG found about 70 percent of users changed what other people in their household ate or drank, and that non-users adopted between 30 and 50 percent of the behavioral changes they saw. Counting that spillover, BCG estimates the market influenced by GLP-1s is about 50 percent larger than the active-user population. In the US, that turns an estimated 16 million active users into roughly 24 million people whose consumption may be affected ^[1].

Some assumptions about taste are being tested too. IFF's UK research found users were more likely than non-users managing their weight to increase consumption of grain-based and baked products, honey and natural syrups, while both groups moved away from artificial sweeteners ^[1]. And although 65 percent of users eat smaller meals more frequently, they still get protein and other nutrients mainly from traditional meals rather than protein bars or functional snacks. Breakfast remains an important nutritional occasion and dinner stays an anchor meal ^[1].

Appetite is not the only thing that changes. IFF found 70 percent of GLP-1 consumers had lost some of the joy of eating and 73 percent reported changed taste preferences, while 66 percent reported some change in mood or personality. The Harris Poll UK found 38 percent of current users reported reduced "food noise," 37 percent less emotional eating and 36 percent fewer cravings ^[1].

Why it matters for patients

These findings are about grocery spending and eating patterns, not about how well the medications work. They suggest that a household's food bill may not fall simply because someone is eating less, since some users spend more per item on protein, produce and fiber-rich foods even while buying fewer products overall ^[1]. They also suggest that partners, children and housemates often change what they eat along with the person taking the drug, which means a prescription can affect a family's diet beyond the patient ^[1]. For anyone thinking about cost, the research points to a possible shift rather than a straightforward saving in the first months. The surveys were conducted in the UK, and whether US shoppers show the same patterns has not been reported ^[1]. The research also does not break out results by specific medication or dose, and the analysis reported no clinical outcomes such as weight or blood sugar changes ^[1].

What remains unclear

Much of the evidence comes from self-reported surveys rather than scanned receipts, so the size of the effect on actual sales is not yet pinned down ^[1]. Nothing in the reporting indicates follow-up dates or new rounds of the research, and it is not yet known how the patterns may differ by drug, by duration of treatment or by whether a person pays out of pocket ^[1]. The analysis also notes that current prescription counts leave out household members whose diets change, so market estimates based only on active users may understate the reach ^[1].